|daily menu » rate the banner | guess the city | one on one|
|May 21st, 2012, 04:28 PM||#1|
10th February 2008
Join Date: Feb 2003
Likes (Received): 251
One to keep an eye out on.
MediPark + Roundthorn
The University Hospital of South Manchester (UHSM) is at the centre of a number of initiatives that can take advantage of sites for the creation of a medical and related services complex as well as general business activity. UHSM is a world-class research hospital and centre of clinical excellence. It is supported academically by the University of Manchester and is fundamentally driven by three core elements: clinical, research and education. MediPark will be an internationally significant health and biotech commercial enterprise directly linked to UHSM and the leading edge research and innovation of the Manchester Academic Health Sciences Centre.
The opportunity has been recognised jointly by UHSM, Manchester City Council and Manchester Airports Group to build upon the well-established concentration of health research, learning and clinical expertise. Manchester MediPark will create a catalyst for growth within the Manchester City Region, which has the ability to makea significant contribution to the UK’s science and innovation agenda. Land to the immediate south of the hospital site is available for the development of the first phase of MediPark and to the immediate north is the Roundthorn Industrial Estate, which offers a number of parcels included within the Enterprise Zone and there is a nearterm
opportunity to create new business floor space on the site, principally in the hospital and medical ancillary support services sector.
Bosses of a 200-acre medical park being developed in Manchester’s Enterprise Zone say they are hopeful of luring global firms to the region in the coming months.
The MediPark is being created by the University Hospital of South Manchester next to Manchester Airports Group’s Airport City scheme.
Speaking at the MIPIM property convention in Cannes, UHSM chairman Felicity Goodey said the process of finding a developer for the scheme would begin within the next two months, with an official launch penciled in for June.
She said talks were already underway with global companies interested in located at MediPark and that she hoped to announce anchor tenants for the project by the end of the year, when preparation work on the site will also start.
Ms Goodey said the aim was to tap into the biotechnology and pharmaceuticals sector, worth an estimated 1bn pounds worldwide and growing at a rate of 12 per cent each year.
She said the MediPark was ideally placed to take advantages of these opportunities because of its proximity to Manchester Airport, the benefits of being part of the Enterprise Zone – such as reduced business rates and simplified planning rules – and the fact Greater Manchester already has a strong life sciences sector.
The city region has described as being in the “European super league” by GlaxoSmithKline.
MediPark comprises 35 acres of UHSM land, 90 acres owned by Royal London Asset Management and 75 by south Manchester-based developer Bluemantle.
UHSM is working with BDP and Urban Strategies on creating the masterlan that will be unveiled in June.
Ms Goodey said: “Sitting next to Airport City, we believe the MediPark is a fantastic opportunity for Greater Manchester to create something that simply doesn’t exist anywhere else in the UK.”
She added the MediPark had “investors knocking on the door” and negotiations were underway “in detail” about attracting them to the site as anchor tenants later in the year.
Website is live. More info will appear in the near future: http://www.manchestermedipark.com/#